Stephen completed his combined M.D-Ph.D. training followed by 4 years of neurosurgical training at UBC. He switched to neuropathology and obtained his Royal College certification in 2007. He completed fellowship training in molecular neuro-oncology at the Massachusetts General Hospital under the mentorship of Dr David Louis (RC Clinician Investigator Program) and molecular genetic pathology at MGH/Harvard Medical School under the supervision of Dr John Iafrate. He currently practices neuropathology at Vancouver General Hospital and is the directors of the Cancer Genetics & Genomics Laboratory and Centre for Clinical Genomics at BC Cancer. His research interests include dissecting the molecular pathology of brain and spine cancers, practical deployment of advanced diagnostic assays including panel- based and whole genome sequencing, and the application of deep learning as a practical diagnostic tool integrating glass- and genome- based pathology features. Relevant papers Levine AB, Schlosser C, Grewal J, Coope R, Jones SJM, Yip S. Rise of the Machines: Advances in Deep Learning for Cancer Diagnosis. Trends in Cancer. Doi: 10.1016/j.trecan.2019.02.002. 2019. Wong D, Lounsbury K, Lum A, Song J, Chan S, LeBlanc V, et al. Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer. Oncogene. 2018. Wong D, Yip S. Machine learning classifies cancer. Nature. 2018;555(7697):446-7. Tarpey PS, Behjati S, Young MD, Martincorena I, Alexandrov LB, Farndon SJ, et al. The driver landscape of sporadic chordoma. Nat Commun. 2017;8(1):890. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226(1):7-16.
High-yield review of molecular pathology with emphasis on the impact on pre-analytical variables, the correlation between molecular features and histology as well as clinical phenotype.
Identify pre-analytic variables that affect molecular testing.
Appreciate key genomic drivers in different malignancies and how they are tested.
Understand next generation sequencing and its impact on molecular diagnostics